Lyell Immunopharma, Inc.
Regulated industrySells to businessesDevelopment stageTags from an AI model reading the company description.
Key Metrics
- Previous Close
- $13.67
- 52-Week Range
- $7.20 – $45.00
- Market Cap
- $444.70M
- P/E (TTM)
- —
- EPS (TTM)
- -12.61
- Dividend Yield
- 0.00%
Advanced Metrics
- Price/Book
- 1.77
- PEG Ratio
- —
- Return on Equity
- -97.79%
- Return on Assets
- -36.90%
- Gross Margin
- 100.00%
- Operating Margin
- -1341693.40%
- Profit Margin
- 0.00%
- Current Ratio
- 4.02
- Debt/Equity
- 0.23
- Total Debt
- $44.28M
- Free Cash Flow
- $-65.90M
- Revenue Growth
- -80.00%
- Earnings Growth
- —
- Enterprise Value
- $208.67M
Market Snapshot
About
Lyell Immunopharma, Inc. is a T-cell reprogramming company developing cell therapies for solid tumors. The company focuses on addressing T-cell exhaustion and enhancing the persistence and functionality of engineered T-cells for cancer treatment. Lyell combines synthetic biology and genetic reprogramming techniques to create next-generation adoptive cell therapies.